- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01838304
Probability Ramp Control of Propofol for EGD
A Prospective, Randomized Comparison of Depth of Sedation With Propofol Titrated by Probability Ramp Control to Control by Anesthesia Providers During Esophagogastroduodenoscopy (EGD)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Administration of propofol to achieve a target of moderate sedation is a challenging task for which anesthesia providers receive minimal training. Undersedation results in a noncompliant patient, while oversedation results in airway obstruction, respiratory depression, and hypotension. Considerable variability in patient pharmacokinetics (the distribution of drug within the body) and pharmacodynamics (the translation of drug concentration to clinical effect) has been demonstrated. The skill of titrating propofol to the desired target and maintaining this state is slowly acquired in the clinical environment of the endoscopy center with frequent reliance on rescue skills. An automated system that facilitates this process would be useful.
Pharmacokinetic models allow us to make predictions of the results of drug administration. If we know the age and size of the patient, we can determine a quantity of propofol that will attain a desired concentration at some point in the future (within the predictive accuracy of the model). If they are old, this is less than if they are young. If they are obese, this is more than if they are thin. By adjusting the dosing, we can achieve similar concentrations at a specified time in a wide range of patients.
Pharmacodynamic models allow us to relate drug concentration to a probability of response. Sensitivity is a randomly distributed variable, and the cumulative probability of response to propofol is well represented by a sigmoid curve. While we do not know the concentration that will suffice for a given individual, we can determine the probability that this individual will lose responsiveness within an interval of concentrations. For example, the probability of loss of responsiveness between 1 µg/ml and 6 µg/ml is around 99%. For any given age and size, an infusion sequence can be determined so that we traverse this interval smoothly. The infusion sequence is determined by minimization of the difference between the simulated probability and the target (1). We predict that 90% of 50 year old 70 kg patients will lose responsiveness between one minute and three minutes after initiating the infusion, and 99% by five minutes. The infusion sequence for this patient is comprised of a bolus of 287 µg/kg followed by an initial infusion of 216 µg/kg/min, with an increase to 550 µg/kg/min after 147 seconds. By selecting the infusion sequence based on the age and size of the patient, all patients will track the same target line. These infusion rates are determined prior to initiation of sedation, and the clinician can verify that they are appropriate for the patient before beginning sedation.
Once the endpoint of adequate sedation is observed, the effect site concentration associated with this endpoint is inferred, and the infusion that will maintain this concentration can be determined. This allows the clinical observation to be translated into an infusion rate, much as a driver accelerates to a desired speed and then engages the cruise control to maintain that speed.
The intent of this study is to demonstrate equivalent safety and efficacy of PRC to control by a skilled clinician.
References
1. Mandel JE, Sarraf E. The Variability of Response to Propofol Is Reduced When a Clinical Observation Is Incorporated in the Control: A Simulation Study. Anesthesia & Analgesia. 2012;114:1221-9.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Endoscopy Center, Perelman Center for Advanced Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- scheduled for elective EGD
Exclusion Criteria:
- Unable to provide informed consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Monitoring
Standard of care sedation by CRNA using proposal with manual recording of drug dosing
|
Manual recording of drug doses determined by CRNA
Other Names:
|
Experimental: Probability ramp control
Propofol titrated to deep sedation using PRC software.
|
Decision support software that calculates propofol doses appropriate for age and weight of the patient
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants Requiring Adjustment in Propofol Dosing
Time Frame: Intraprocedure (average of 9 minutes)
|
Following initial sedation, an infusion rate for propofol is determined by the CRNA (control) or software (experimental).
If this rate is appropriate for the duration of the brief procedure, no adjustment to the rate will be required.
A greater requirement for rate changes suggests that the anesthesia provider needs to be immediately available to perform these adjustments.
|
Intraprocedure (average of 9 minutes)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Decrease in Minute Ventilation From Baseline
Time Frame: Duration of sedation (average of 25 minutes)
|
Minute ventilation as determined by respiratory inductance plethysmography from initiation of sedation until emergence.
|
Duration of sedation (average of 25 minutes)
|
Time Spent Below a Saturation of 80%
Time Frame: Duration of sedation (mean 25 minutes)
|
Number of seconds spent below saturation of 80%, reported as the total per group
|
Duration of sedation (mean 25 minutes)
|
Procedure Time
Time Frame: Procedure time (average of 9 minutes)
|
Time from endoscopic intubation until completion of the procedure.
This is not really an outcome measure, but is used to assess balance between groups.
|
Procedure time (average of 9 minutes)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jeff E Mandel, MD MS, University of Pennsylvania
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 817166
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gastrointestinal Disease
-
Ethicon Endo-SurgeryCompleted
-
Jiangxi University of Traditional Chinese MedicineThe First Affiliated Hospital of Nanchang University; Second Affiliated Hospital... and other collaboratorsCompletedGastrointestinal DiseaseChina
-
Massachusetts General HospitalEnrolling by invitationGastrointestinal Dysfunction | Gastrointestinal DiseaseUnited States
-
Pharmbio Korea Co., Ltd.CompletedColonic Diseases | Digestive System Disease | Gastrointestinal Disease | Intestinal DiseaseKorea, Republic of
-
Pharmbio Korea Co., Ltd.RecruitingColonic Diseases | Digestive System Disease | Gastrointestinal Disease | Intestinal DiseaseKorea, Republic of
-
Shandong UniversityUnknownGastrointestinal DiseaseChina
-
Methodist Health SystemEnrolling by invitation
-
Massachusetts General HospitalBill and Melinda Gates FoundationEnrolling by invitationGastrointestinal DiseaseUnited States
-
Changhai HospitalCompletedGastrointestinal DiseaseChina
-
Shandong UniversityUnknown
Clinical Trials on Monitoring
-
University of FloridaNational Institute of Neurological Disorders and Stroke (NINDS); National Institutes... and other collaboratorsActive, not recruitingPain | DeliriumUnited States
-
University of FloridaNational Institute of Neurological Disorders and Stroke (NINDS); National Institute...RecruitingPain | Delirium | Confusion | Critical IllnessUnited States
-
National Taiwan University HospitalRecruiting
-
UNC Lineberger Comprehensive Cancer CenterThe Thoracic Surgery FoundationCompletedThoracic SurgeryUnited States
-
Biotronik FranceBiotronik SE & Co. KGCompletedBradycardia | Pacemaker, ArtificialFrance
-
University of AarhusCompletedChronic Obstructive Pulmonary Disease, COPDDenmark
-
Fondazione IRCCS Istituto Nazionale dei Tumori,...Merck Sharp & Dohme LLCCompleted
-
Vanderbilt UniversityTerminatedAspiration, RespiratoryUnited States
-
Carilion ClinicJohns Hopkins University; Virginia Commonwealth University; Medstar Health Research... and other collaboratorsWithdrawnChest Pain | Acute Coronary Syndrome | Telemetry | Health Care Resource Utilization
-
CHU de ReimsUnknownDiabetic Foot - Telemedical MonitoringFrance